Canada’s Drug Agency Issues Recommendation to Reimburse Yorvipath® (palopegteriparatide injection) With Conditions for Eligible Adults With Chronic Hypoparathyroidism


MONTREAL, Sept. 03, 2026 (GLOBE NEWSWIRE) — Pendopharm, a division of Pharmascience Inc., in collaboration with Ascendis Pharma A/S, today announced that Canada’s Drug Agency, or CDA-AMC, has recommended that Yorvipath® (palopegteriparatide injection) be reimbursed with conditions by participating public drug plans for eligible adults with chronic hypoparathyroidism that are not adequately controlled with conventional therapy.



Source link

  • Related Posts

    S&P/TSX composite rises 1.5% amid materials gains, U.S. stock markets also higher

    TORONTO — Canada’s main stock index rose 1.5 per cent Thursday, helped by gains in materials and technology stocks, as U.S. markets also gained ground. The S&P/TSX composite index was…

    Veteran Capital Corp. Announces Resumption of Trading on the TSX Venture Exchange

    CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION: This news release includes certain “forward-looking statements” under applicable Canadian securities legislation. Forward-looking statements include, but are not limited to, statements with respect to resumption of…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    NWSL Power Rankings: Gotham FC still surging as Orlando Pride look for restart

    NWSL Power Rankings: Gotham FC still surging as Orlando Pride look for restart

    Lenovo’s Project AeroBlade Fanless Laptop Takes Thin and Light to the Extreme

    Lenovo’s Project AeroBlade Fanless Laptop Takes Thin and Light to the Extreme

    Allegiant Air Cancels Flights To These 35 Airports: See Full List Now

    Allegiant Air Cancels Flights To These 35 Airports: See Full List Now

    How to Look Elegant For Fall: These Pants With These Flats

    How to Look Elegant For Fall: These Pants With These Flats

    📈 The big building tour

    📈 The big building tour

    S&P/TSX composite rises 1.5% amid materials gains, U.S. stock markets also higher

    S&P/TSX composite rises 1.5% amid materials gains, U.S. stock markets also higher